The EU’s Dispute with AstraZeneca Intensifies

The EU’s Dispute with AstraZeneca Intensifies

The conflict between the European Union and AstraZeneca is coming to a head. AstraZeneca maintains that less than half of the pre-financed order will be delivered. The latter is causing outrage and raises suspicion in Brussels.

The pharmaceutical company representative of AstraZeneca had to face the questions of the EU Commission while also listening to strong criticism from the experts of the 27 EU member states. Nonetheless, the companies answer remained the same: AstraZeneca would deliver significantly less vaccine than promised, in fact probably less than half of the agreed doses.

A stance, completely unacceptable, as Stella Kyriakides, the EU Commissioner responsible for health, emphasized after the questioning session.

The European Commission has already made advance payments totaling € 336 million for AstraZeneca. The payment should finance the development of the vaccine and its production. The goal: The vaccine should be delivered immediately after approval, which is expected this week.

Given the recent developments, Commissioner Kyriakides goes as far as suspecting that AstraZeneca might have supplied the vaccine co-financed by the EU to other non-EU countries. Meanwhile, AstraZeneca has stated problems with a Belgian supplier as its cause for the delivery failures.

Added to the delivery issue are concerns about the effectiveness of the vaccine. AstraZeneca yesterday denied media reports that the vaccine is said to have little effect on the elderly. Different media outlets had reported unanimously, citing German government circles, that the vaccine was only eight percent effective in people over 65. According to AstraZeneca, this is “a complete falsehood.”

AstraZeneca CEO Pascal Soriot is nonetheless coming under increasing pressure. At the digital world economic forum in Davos, he didn’t say a word about Brussels’ allegations. Instead, he appealed for global solidarity in the fight against the coronavirus.

EU Council President Charles Michel, who speaks of a great deal of impatience among the population, is also increasingly intervening in the dispute. He said the entire population was suffering from bottlenecks in vaccine production and vaccination.

The EU expected the contracts confirmed by the pharmaceutical companies to be complied with, said Michel. The EU Council President emphasized that the EU could also use legal means to ensure compliance with the treaties without going into any further detail.

(Photo: WikimediaCommons CC BY-SA 4.0)

newsletter
Join our mailing list and never miss an update !
EU nutrition debate enters the next round

EU nutrition debate enters the next round

A recent survey conducted by the World Wildlife Fund (WWF) has found that Europeans want the EU to do more to help them make healthier and more environmentally friendly

European Parliament Hosts Third Gender Equality Week

European Parliament Hosts Third Gender Equality Week

The European Parliament's third European Gender Equality Week begins today and will continue until October 30th with several parliamentary committees and delegations hosting sessions addressing gender equality issues in their

Czech Presidency gives the EU a valuable opportunity to re-think ‘Farm to Fork’

Czech Presidency gives the EU a valuable opportunity to re-think ‘Farm to Fork’

The Czech Republic has assumed the Presidency of the EU Council at a critical moment for the bloc, which is struggling to find answers to the conflicting demands posed by